I think there are multiple reasons for a breakout here. First off, revenue growth. 97 revs were 20 mill. 98 were 52 mill. With the series of deals that they have announced this quarter (Pfizer, NCI, smithklin, parke-Davis, etc.) I am looking for a much bigger 99. (Possibly 100 mill, although this may be optimistic.)
Additionally, this is a leading company in the genomics field, which is relatively "hot", although not compared with the nets. This "Hotness" is verified by the recent price moves in affx and mlnm. Additionally, Incyte in it's quarterly gave indications that affx might be winning the patent war by stating that 99 revenues would not meet expectations due to affx patent dispute.
Another possible factor is the fact that a lot of people have been dumping INCY lately have possibly shifted that cash into affx.
At any rate, a lot of people have realized for a long time that this company had tremendous potential. With recent events (ie revenue growth, flurry of deals, and possible edge over INCY in patent disputes) this may be a stock whose time has come.
The technicals backing this up are moving over 41 today after several days of high volume. This is why I predicted the price increase to come in the next week or so, due to the chart. However, I am not really a chartist, so take that with a grain of salt. We'll see. |
